Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Botnar Research Centre, Old Road, Oxford, UK.
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Sci Rep. 2019 Jun 20;9(1):8941. doi: 10.1038/s41598-019-45435-1.
There is emerging evidence of the impact of infections on rheumatoid arthritis pathogenesis and flares. We aimed to study the association between antibiotic use (and timing of use), and the occurrence of flares in patients with RA. We nested a self-controlled case series (SCCS) of patients who have RA flares within a newly diagnosed RA cohort (n = 31,992) from the UK Clinical Practice Research Datalink (CPRD) GOLD dataset. We determined associations between exposure to antibiotics (beta-lactam, imidazole, macrolide, nitrofurantoin, quinolone, sulphonamide and trimethoprim, and tetracycline) and the occurrence of RA flares. Conditional fixed-effects Poisson regression models were used to determine incidence rate ratios (IRR), offset by the natural logarithm of risk periods. A total of 1,192 (3.7%) of RA subjects had one or more flare/s during the study period, and were therefore included. Use of sulphonamide and trimethoprim was associated with an increased risk of RA flare at 29-90 days (IRR 1.71, CI 1.12-2.59, p = 0.012); 91-183 days (IRR 1.57, CI 1.06-2.33, p = 0.025); and 184-365 days (IRR 1.44, CI 1.03-2.02, p = 0.033) after commencement of antibiotic treatment. No other antibiotic group/s appear associated with RA flare/s risk. Usage of sulphonamide and trimethoprim antibiotics, is associated with a 70% increased risk of RA flare at 1-3 months, which decreases but remains significant up to 12 months after treatment. We hypothesise that the delayed onset of RA flares after specific antibiotics is mediated through the gut or urinary microbiomes. Further epidemiological and mechanistic research is needed to determine the role of infections in RA.
越来越多的证据表明感染对类风湿关节炎发病机制和发作的影响。我们旨在研究抗生素使用(及其使用时间)与类风湿关节炎患者发作之间的关联。我们在英国临床实践研究数据链(CPRD)GOLD 数据集的新诊断类风湿关节炎队列中嵌套了类风湿关节炎发作的自身对照病例系列研究(SCCS)(n=31992)。我们确定了暴露于抗生素(β-内酰胺类、咪唑类、大环内酯类、呋喃妥因、喹诺酮类、磺胺类和甲氧苄啶类以及四环素类)与类风湿关节炎发作之间的关联。使用条件固定效应泊松回归模型来确定发病率比(IRR),并通过风险期的自然对数进行偏移。在研究期间,共有 1192 名(3.7%)类风湿关节炎患者发生了一次或多次发作/发作,因此被纳入研究。磺胺类和甲氧苄啶的使用与 29-90 天(IRR 1.71,CI 1.12-2.59,p=0.012)、91-183 天(IRR 1.57,CI 1.06-2.33,p=0.025)和 184-365 天(IRR 1.44,CI 1.03-2.02,p=0.033)后开始抗生素治疗的类风湿关节炎发作风险增加相关。没有其他抗生素组/与类风湿关节炎发作风险相关。抗生素磺胺类和甲氧苄啶的使用与类风湿关节炎发作的风险增加 70%相关,在治疗后 1-3 个月内,这种风险增加,但在 12 个月后仍然显著。我们假设特定抗生素后类风湿关节炎发作的延迟发作是通过肠道或尿路微生物组介导的。需要进一步的流行病学和机制研究来确定感染在类风湿关节炎中的作用。